Multiple Myeloma

Thalidomide Pharmion application to be resubmitted to EMEA for multiple myeloma

Published in Hematology Week, June 28th, 2004

Pharmion Corporation (PHRM) announced its intent to provide additional clinical data and resubmit its application with the European Medicines Evaluation Agency (EMEA) for the use of Thalidomide Pharmion 50 mg to treat patients with multiple myeloma.

The company is targeting a resubmission with additional clinical data from ongoing studies in both relapsed/refractory and newly diagnosed patients.

Pharmion also reaffirmed its 2004 sales guidance of $51-56 million in named patient and compassionate use sales of thalidomide, provided by the company on May 3, 2004. This was updated from previous guidance of $38-43 million.

The company...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hematology Week

Source: Hematology Week (2004-06-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry